UCB SA (0NZT)
LSE
Real-time Data
07:00 AM
Day's Range
200.0052 wk Range
198.00Overview - 0NZT - UCB SA
Key Statistics
Valuation
Enterprise Value
16.11B
P/E (Trailing)
‪120.47‬
Price / Sales (TTM)
‪8.15‬
Price / Book
‪4.29‬
EV / EBITDA
‪14.20‬
Profitability
Profit Margin
‪6.45%‬
Operating Margin
‪10.64%‬
Return on Assets
‪2.14%‬
Return on Equity
‪3.69%‬
Ownership
Shares Outstanding
190.66M
Float
120.27M
Held by Insiders
‪38.03%‬
Held by Institutions
‪40.79%‬
Price stats
Beta
‪0.33‬
50-Day Avg
‪217.75‬
200-Day Avg
‪244.17‬
Dividends
Payout Ratio
‪78.23%‬
Frequency
Annual
Market Cap - 0NZT - UCB SA
Peers - 0NZT - UCB SA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0NZTLSEUCB SA41.70BMarket Cap-23.88%52-week change120.47P/E (Trailing)‪6.45%‬Profit Margin
- 0MGBLSEGenmab A/S198.39BMarket Cap+15.12%52-week change33.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock128.96BMarket Cap+20.00%52-week change0.53P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.95.05BMarket Cap+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.79.08BMarket Cap+20.99%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE49.68BMarket Cap+27.60%52-week change40.07P/E (Trailing)‪-47.51%‬Profit Margin
- 0K91LSENorthern Trust Corporation37.94BMarket Cap+23.65%52-week change0.24P/E (Trailing)‪24.67%‬Profit Margin
Profile Summary - 0NZT - UCB SA
About
UCB SA is a multinational biopharmaceutical company headquartered in Brussels, Belgium, founded in 1928 by Emmanuel Janssen. It specializes in developing innovative medicines for severe neurological and immunological diseases, including epilepsy, Parkinson's disease, Crohn's disease, psoriasis, and autoimmune…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
